Damora Therapeutics
DMRA
20.24
+0.69
+3.53%
Damora Therapeutics
US · DMRA
#3109 by market cap
Listed 1970
20.24
+0.69
+3.53%
Live - 5344 symbols - heartbeat 151s ago
· 2026-10-07 19:54
After-hours
20.24
0.00%
- Market cap
- 1.25B
- P/E (TTM)i
- -77.85
- P/Bi
- 3.24
- EPSi
- -3.98
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on DMRA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 112.30% +0.02pp
- Institutions
- 124
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund46.16%
Hedge Fund38.54%
VC/PE Fund19.41%
Private Company6.73%
Public Company1.26%
Individual/Insider1.07%
Government Pension Fund0.20%
Top holders as of 2026-06-30
FMR
14.96% · 9.23M sh
Fairmount Funds Management LLC
14.11% · 8.71M sh
Avoro Capital Advisors LLC
6.13% · 3.78M sh
VR Management, LLC
5.84% · 3.60M sh
BlackRock
5.12% · 3.16M sh
Forbion Capital Partners B.V.
3.95% · 2.44M sh
RA Capital Management, L.P.
3.89% · 2.40M sh
Viking Global Investors LP
3.74% · 2.31M sh
Janus Henderson Group plc
3.70% · 2.28M sh
Panorama Holdings, LLC
3.31% · 2.05M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Fairmount Funds Management LLC | -- | 14.11% |
| Jennifer Jarrett | Chief Executive Officer | 0.83% |
| Julianne Bruno | Independent Director | 0.22% |
| Hans Schambye | Chief Executive Officer | 0.01% |
| Garrett Winslow | Senior Vice President | 0.00% |
| Lori Firmani | Interim Chief Financial Officer | 0.00% |
| Jonathan Freve | Chief Financial Officer | 0.00% |
| Carl Goldfischer | Independent Chairperson | 0.00% |
| David Shapiro | Independent Director & Member of the Clinical Advisory Board - Liver cirrhosis | -- |
| Amy Wechsler | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24 | Jennifer Jarrett | Chief Executive Officer | Open Market Acquisition | +12,500 | $20.23 |
| 2026-08-11 | Andrew Cheng | Director | Other Derivative Acquisition | +30,350 | $31.00 |
| 2026-08-04 | Lori Firmani | Interim Chief Financial Officer | Intent to Sell (Form 144) | -1,800 | $31.10 |
| 2026-07-05 | Garrett Winslow | Senior Vice President | Derivative Exercise and Sale | -245 | $29.98 |
| 2026-07-02 | Garrett Winslow | Senior Vice President | Derivative Exercise and Retained | +435 | -- |
| 2026-06-21 | Lori Firmani | Interim Chief Financial Officer | Intent to Sell (Form 144) | -7,615 | $25.36 |
| 2026-04-30 | Brian Burkavage | Senior VP of Finance, Principal Financial & Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-29 | Jennifer Jarrett | Chief Executive Officer | Other Acquisition | +500,000 | -- |
| 2026-03-29 | Jennifer Jarrett | Chief Executive Officer | Other Derivative Acquisition | +1,500,000 | $25.50 |
| 2026-03-22 | Michael Landsittel | Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Christopher Cain | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Garrett Winslow | Senior Vice President | Other Derivative Acquisition | +250,000 | $23.05 |
| 2026-03-22 | Cameron Turtle | Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Peter Harwin | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-03-22 | Julianne Bruno | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 |
| 2026-02-08 | Fairmount Funds Management LLC | -- | Derivative Exercise and Retained | +8,713,000 | -- |
| 2026-02-08 | Julianne Bruno | Independent Director | Derivative Exercise and Retained | +129,000 | -- |
| 2026-01-04 | Becker Hewes | Chief Medical Officer | Other Acquisition | +264,629 | -- |
| 2026-01-04 | Becker Hewes | Chief Medical Officer | Other Derivative Acquisition | +528,603 | $21.82 |
| 2026-01-04 | Sherwin Sattarzadeh | Chief Operating Officer | Other Acquisition | +190,376 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.